Sermonix Exercises 3.15M Warrants, Distributes 4.73M LeonaBio Shares
LONA has more than doubled off its 52-week low of $3.6.
Summary
Sermonix Pharmaceuticals is exercising warrants for 3.15M LeonaBio shares and distributing 4.73M shares to its investors and a creditor, effective October 26, 2026, creating a large potential overhang.
Key Events · Ownership and Investor Activity · LONA
-
Warrant Exercise and Distributions
Sermonix exercised prefunded warrants for 3,149,470 shares and declared a distribution-in-kind of 4,725,754 shares, both effective October 26, 2026.
-
Creditor Assignment
Sermonix assigned 170,940 shares to a creditor in satisfaction of amounts owed, with remittance on or shortly after October 26, 2026.
-
Ownership Concentration
Sermonix and David Portman report shared voting and dispositive power over 5,502,402 shares, representing 36.9% of LeonaBio's outstanding common stock.
-
Distribution Recipients
Perceptive Xontogeny Venture Fund II, LP and HPW Asset Management Limited will each receive more than 5% of LeonaBio's common stock through the distribution.
Analysis · LONA · Life Sciences
Sermonix Pharmaceuticals, the licensor of LeonaBio's lead drug lasofoxifene, is converting its prefunded warrants into 3.15 million shares and distributing another 4.73 million shares to its own investors and a creditor, all effective October 26, 2026. This creates a significant overhang: roughly 5.5 million shares, or 36.9% of the company, will be in the hands of Sermonix's limited partners and a creditor rather than a single strategic holder. The distribution-in-kind to Perceptive Xontogeny and HPW Asset Management means these shares could be sold into the market once registered, adding supply pressure to a stock already facing a going-concern warning from its Q2 10-Q.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1963 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LONA was trading at $7.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.6M. The 52-week trading range was $3.60 to $40.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.